Holdaway I M, Ibbertson H K, Croxson M S, Harvey V, Boulton J, Knox B S
Department of Endocrinology, Auckland Hospital, New Zealand.
Am J Clin Oncol. 1988;11 Suppl 2:S123-6. doi: 10.1097/00000421-198801102-00031.
The depot LH-RH agonist Zoladex was used to treat 38 patients with previously untreated symptomatic stage D2 prostate carcinoma. Side effects were minimal and patient acceptability excellent, although temporary tumor flare occurred in 11% of patients. Eighty-four percent experienced subjective improvement and 87% had objective evidence of initial disease stabilization or remission lasting 3 months. Serum levels of gonadotrophin and free testosterone as well as androgens of adrenal origin fell significantly with treatment. Long-term survival to date appears at least as good as that described for conventional endocrine therapy.
长效促性腺激素释放激素（LH-RH）激动剂诺雷德用于治疗38例未经治疗的有症状的D2期前列腺癌患者。尽管11%的患者出现了短暂的肿瘤 flare，但副作用极小，患者接受度良好。84%的患者主观症状改善，87%的患者有客观证据表明初始疾病稳定或缓解持续3个月。治疗后，促性腺激素、游离睾酮以及肾上腺源性雄激素的血清水平显著下降。迄今为止，长期生存率似乎至少与传统内分泌治疗所描述的一样好。
